Endpoints News 生物医药· Ayisha Sharma·· 2026-10-13AI 评分25
Syndax 终止 Niktimvo 治疗特发性肺纤维化(IPF)的开发,II 期试验失败
Syndax's lung disease ambitions for Niktimvo end with a Phase 2 failure
AI 导读
Syndax 在 Niktimvo 治疗特发性肺纤维化(IPF)的 II 期试验失败后,终止了该药在该适应症上的开发。此次失败意味着 Niktimvo 不再推进 IPF 适应症。
正文
Syndax is ending development of Niktimvo in a rare lung disease called idiopathic pulmonary fibrosis (IPF) after the treatment flunked a mid-stage trial.
The company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news